Business context and reporting period
Issuer: The filing is for Organovo Holdings, Inc. (NYSE MKT: ONVO), not Vivosim Labs, Inc. It is a Form 10-K for the fiscal year ended March 31, 2015; it does not provide a standalone 2014 fourth-quarter financial summary. The company develops and commercializes 3D-bioprinted human tissues, with its first commercial offering, exVive3D Human Liver Tissue, launched broadly in November 2014.
Key financial metrics
Amounts below are in U.S. dollars; financial statement figures are rounded to millions unless otherwise noted.
| Metric | FY ended Mar. 31, 2015 | FY ended Mar. 31, 2014 |
|---|---|---|
| Revenue | $0.571 million | $0.379 million |
| Operating expenses | $30.9 million | $21.0 million |
| Operating loss | $30.3 million | $20.6 million |
| Net loss | $30.1 million | $25.8 million |
| Net loss per share | $0.38 | $0.35 |
| Cash used in operating activities | $19.6 million | $15.6 million |
| Cash and cash equivalents at year-end | $50.1 million | $48.2 million |
| Working capital | $46.5 million | $47.3 million |
| Total assets | $53.5 million | $50.2 million |
| Total liabilities | $4.8 million | $1.9 million |
Revenue comprised $314,000 of product and service revenue, $134,000 of collaboration revenue, and $123,000 of grant revenue. The filing does not separately report gross profit or gross margin. Operating and net margins were deeply negative. Debt was not a significant year-end funding source: reported capital lease obligations were approximately $5,000, and warrant liabilities were $126,000.
Material changes versus the prior comparable year
- Revenue rose 50%, to $571,000, including $314,000 in commercial product and service revenue after the liver-tissue launch. Collaboration revenue declined as a larger prior agreement was completed.
- Operating expenses increased 47% to $30.9 million: research and development rose 61% to $12.9 million, while selling, general and administrative expense rose 38% to $17.9 million. Management cited increased staffing, commercialization activity, facilities, and stock-based compensation.
- Operating loss widened from $20.6 million to $30.3 million. Net loss increased less, from $25.8 million to $30.1 million, as other expense improved substantially: the prior year included a $5.1 million noncash loss from revaluing warrant liabilities; the current year recorded a $0.2 million gain.
- Operating cash use increased to $19.6 million. Financing provided $23.1 million, including approximately $22.3 million net proceeds from at-the-market stock sales. Cash rose by $2.0 million over the year.
- Stock-based compensation increased to $7.0 million from $4.6 million. Shares outstanding at year-end were 81.5 million, up from 78.1 million.
Outlook, risks, contingencies and unusual items
- Management stated that available resources and its operating plan were expected to fund the business for at least the next 12 months. It also said additional capital would be needed to further develop and commercialize its products; future financing availability and terms were uncertain, and equity financing could dilute stockholders.
- No quantified revenue, earnings, or cash-flow guidance was provided. The company expected continued research, development, and commercialization spending and anticipated operating losses.
- Key risks include limited commercial history and low revenue relative to expenses; uncertain customer adoption and technical performance; dependence on collaborations and third-party human-cell supply; competition; intellectual-property protection; and lengthy, uncertain regulation for therapeutic tissue products. Management noted that GLP compliance had not been independently certified.
- A dispute with Spencer Trask Ventures over alleged fees, warrants, and confidentiality obligations remained in arbitration. The company disputed the claims and had recorded no loss accrual, stating that a loss was not assessed as probable or reasonably estimable.
- Warrant-liability valuations rely on Level 3 assumptions and can create significant noncash earnings volatility. The company also reported $7.1 million of future operating lease obligations.
- Subsequent to year-end, Organovo entered a multi-year research collaboration with Merck on April 17, 2015, covering access to its liver-tissue service and development of custom tissue models.
- The independent auditor issued an unqualified opinion on the financial statements and on internal control over financial reporting as of March 31, 2015.
Most important facts for investors to verify
- Confirm the issuer and period: this is Organovo Holdings’ FY2015 10-K, not a Vivosim Labs filing or a standalone 2014 Q4 report.
- Review subsequent quarterly filings for commercial revenue growth, repeat customers, product economics, and whether revenue scales relative to operating costs.
- Track cash burn and financing: the stated 12-month funding assessment is management’s estimate, and further capital may be required.
- Check the status and potential financial impact of the Spencer Trask arbitration and other contingencies.
- Assess dilution from equity issuance, outstanding options and warrants, and the company’s remaining financing capacity.
- Verify progress on regulatory and technical validation, especially for therapeutic applications and any claims of GLP-ready data.